The human immunodeficiency virus-1 (HIV-1) enters target cells by binding its envelope
glycoprotein gp120 to the CD4 receptor and/or coreceptors such as CC chemokine receptor …

The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …

Tacrolimus is the mainstay immunosuppressant drug used after solid organ and
hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and …

Background The calcineurin inhibitors cyclosporine (INN, ciclosporin) and tacrolimus have a
narrow therapeutic index and show considerable interindividual variability in their …

Drug lag, recently discussed extensively in Japan, can be divided into two phases: clinical
development time and application review time. The former factor is still an important problem …

Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose
to achieve therapeutic exposure compared with nonexpressers. This randomized‐controlled …

The cytochrome P450 3A (CYP3A) subfamily members are the most abundant and important
drug-metabolizing enzymes in humans, and wide interindividual variability in CYP3A …

Abstract Cytochrome P450 (CYP) 3A4 is responsible for most CYP3A-mediated drug
metabolism but the minor isoforms CYP3A5, CYP3A7 and CYP3A43 also contribute …

The aim of a PharmGKB VIP summary is to provide a simple overview of a gene with respect
to drug effects. In some cases, there may be extensive evidence of variants that have known …

ABSTRACT Introduction: Tacrolimus (Tac) is effective in preventing acute rejection but has
considerable toxicity and inter-individual variability in pharmacokinetics and …